Brent Fisse LawyersSpecialising in Trade Practices, Competition Law and E-Commerce
Home us world politics business/finance technology health more topics education literature self-help science home » non-hodgkin lymphoma title non-hodgkin lymphoma pub. order viagra Date march 2010 source current medical literature: leukemia & lymphoma;2010, vol. 18 issue 1, p20 source type academic journal doc. buy generic viagra Type article abstract this article reviews several articles on non-hodgkin lymphoma, including "phase i study of the humanized anti-cd40 monoclonal antibody dacetuzumab in refractory or recurrent non-hodgkin's lymphoma," by r. Advani, "pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma," by n. over the counter viagra similar drug S. Anderson et al. viagra for sale And "impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large b cell lymphoma," by t. S. Fenske. Accession # 49789728 tags: lymphomas;  monoclonal antibodies;  rituximab   related articles radioimmunotherapy of non-hodgkin's lymphomas.  cheson, bruce d.  // current drug targets;oct2006, vol. 7 issue 10, p1293 the availability of active monoclonal antibodies has altered the treatment paradigms for patients with non-hodgkin's lymphomas (nhl). Nevertheless, some patients do not respond, while almost all of the others eventually relapse and require additional treatment. Thus, more effective alternatives... online generic viagra Rituximab the first monoclonal antibody approved for the treatment of lymphoma.  grillo-lopez, a. J. ; white, c. A. ; dallaire, b. K. viagra canada ; varns, c. L. buy viagra for cheap ; shen, c. D. ; wei, a. ; leonard, j. E. mg does viagra come ; mcclure, a. buy viagra online cheap with no prescription ; weaver, r. ; cairelli, s. buy viagra for cheap ; rosenberg, j.  // current pharmaceutical biotechnology;jul2000, vol. viagra alternatives uk 1 issue 1, p1 rituximab, a genetically engineered monoclonal chimeric antibody, targets the cd20 antigen expressed on b cells. It was approved by the us food and drug administration on november 26, 1997, for the indication of relapsed or refractory, cd20-positive, b-cell, low-grade or follicular non-hodgkins... cheap generic viagra Rituximab retherapy in patients with relapsed aggressive b cell and mantle cell lymphoma.  borgerding, andrea; hasenkamp, justin; gla�, bertram; wulf, gerald; tr�mper, lorenz // annals of hematology;mar2010, vol. 89 issue 3, p283 neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rit.

Brent Fisse has extensive experience in trade practices and competition law, corporate regulation and e-commerce. He has acted for clients in a wide range of industries including information technology, health, telecommunications, energy, transport, motor vehicles, music, metals, retail grocery, financial services, sport, tourism. recruitment and publishing and broadcasting. He has also acted for several regulatory agencies.

Brent became a partner of Gilbert + Tobin in 1995, after acting for the firm for two years as a consultant. At Gilbert + Tobin he practised mainly in trade practices and competition law and telecommunications regulation, often for Optus against Telstra in the mid-to-late 1990s. With Greg Corrigan of Tankstream Systems, he also developed G+T online trade practices compliance training programs for many leading Australian companies. Since retiring from Gilbert + Tobin in 2004, Brent has run his own specialist trade practices advisory practice. He also continues to develop online compliance applications with Greg Corrigan and Tankstream Systems.

In 1995 Brent advised the ACCC on alternative sanctions against corporations, in the form of draft legislative proposals and a commentary on corporate probation and community service orders. More recently, he advised the Commerce Commission of NZ in a range of competition law matters. In 2010, 2011 and 2012 he assisted the Federal Court in running workshops on cartel offences and criminal cartel trisls.

Brent has assisted in the work of various law reform agencies, including: the SA Penal Methods Reform Committee 1973-1974 (consultant); the ALRC (Powers of Criminal Investigation 1974 (consultant); Compliance with the Trade Practices Act 1994 (Commissioner part-time); Principled Regulation: Civil and Administrative Penalties in Australian Federal Regulation 2002) (member, Advisory Committee)); and the NSW Law Reform Commission (part-time Commissioner 1990-1997). He acted as a consultant to the Attorney-General’s Department in 1974-1975 (Federal Criminal Code project), and as a member of the drafting committee for AS 3806 Compliance Programs in 1997-1998 and 2005-2006.

Brent is the co-author (with Caron Beaton-Wells) of Australian Cartel Regulation, published by Cambridge University Press in February 2011. Other books and papers include: Corporations, Crime and Accountability (with John Braithwaite. 1993), The Impact of Publicity on Corporate Offenders (with John Braithwaite, 1983), Securities Regulation in Australia and New Zealand (co-editor 1st & 2nd eds with Gordon Walker and Ian Ramsay); “Reconstructing Corporate Criminal Law: Deterrence, Retribution, Fault and Sanctions” (1983) 56 Southern California Law Review 1145; and the fifth edition of Howard’s Criminal Law (1990).


Brent taught at the University of Adelaide Law School from 1964-1985 and from 1985-1995 at the University of Sydney where he was a professor of law. His other academic positions have included: Bicentennial Fellow, University of Pennsylvania (1968-1969); Research Professor, University of Delaware, 1981-1982; and Mitchell Distinguished Visiting Professor, Trinity University, San Antonio, 1984. He is an adjunct professor of law at the University of Sydney.

Brent is a member of the American Bar Association Antitrust Section, SIMA and the Law Council of Australia’s Competition and Consumer Committee. He is the managing director of Lexpert Publications Pty Ltd.



© Brent Fisse 2006